S-1 + capecitabine

S-1 + capecitabine refers to the comparative clinical evaluation of two oral fluoropyrimidine-based chemotherapy regimens, S-1 and capecitabine, specifically within a randomized phase II trial conducted by the National Cancer Center, Korea. S-1 is a three-component formulation consisting of tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor), designed to optimize 5-FU levels and minimize gastrointestinal toxicity. Capecitabine is an oral fluoropyrimidine carbamate that undergoes a three-step enzymatic conversion to 5-fluorouracil, primarily within tumor tissue. Both agents function as antimetabolites that inhibit thymidylate synthase, leading to the depletion of thymidine triphosphate and the subsequent inhibition of DNA synthesis and repair. The trial focused on assessing the efficacy and safety of these oral agents as first-line therapy for elderly patients or those with poor performance status suffering from recurrent or metastatic gastric cancer, providing a more convenient alternative to traditional intravenous 5-FU infusions.

Brand names

TS-1TS1TS 1Xeloda

Other names

S-1S1S 1capecitabine